IDHQ - ETF AI Analysis
Top Page
Invesco S&P International Developed High Quality ETF (IDHQ)
Rating:61Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains over the past month, three months, and year to date, indicating positive recent momentum.
High-Quality Leading Holdings
Several of the largest positions, especially in technology and health care, have delivered strong year-to-date results, helping drive the fund’s returns.
Broad International Diversification
The fund spreads its investments across many developed countries, including Japan, the UK, the U.S., and several European markets, which helps reduce reliance on any single economy.
Negative Factors
Mixed Performance Among Top Holdings
A few major positions, such as Roche and Safran, have been weak this year, which can drag on overall performance if the trend continues.
Moderate Expense Ratio
The fund’s fee is not especially high but is also not among the cheapest ETFs, which slightly reduces net returns over time.
Sector Imbalance
The portfolio has relatively low exposure to areas like real estate and energy, which may limit benefits if those sectors outperform.
IDHQ vs. SPDR S&P 500 ETF (SPY)
AUM869.62M
RegionDeveloped Markets
Expense Ratio0.29%
Beta0.83
IssuerInvesco
Inception DateJun 13, 2007
Dividend Yield1.92%
Asset ClassEquity
Index TrackedS&P Quality Developed Ex-U.S. LargeMidCap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume147,598
30 Day Avg. Volume93,286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.83Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering193
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDHQ Summary
The Invesco S&P International Developed High Quality ETF (IDHQ) tracks the S&P Quality Developed Ex-U.S. LargeMidCap Index, focusing on financially strong companies in developed countries outside the U.S. It holds well-known names like ASML Holding and Novartis, and spreads investments across sectors such as industrials, technology, and health care, with major exposure to markets like Japan, the UK, and Switzerland. Someone might invest in IDHQ to diversify beyond the U.S. and seek long-term growth from high-quality international companies. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?The Invesco S&P International Developed High Quality ETF (IDHQ) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a specialized strategy of selecting high-quality international companies. The added cost reflects the fund's meticulous approach to targeting financially strong firms.
What would affect this ETF?Positive drivers for IDHQ include potential growth in developed markets outside the U.S., particularly in sectors like healthcare and technology, which are heavily weighted in the ETF and often benefit from innovation and stable demand. However, negative factors could arise from global economic slowdowns, regulatory changes in key regions, or currency fluctuations that impact international companies' profitability. The ETF's focus on high-quality companies may help mitigate risks but does not eliminate exposure to broader market challenges.
IDHQ Top 10 Holdings
IDHQ’s story is all about high‑quality giants outside the U.S., with a clear tilt toward European and Asian leaders. ASML and Tokyo Electron are the fund’s main engines right now, riding strong demand for chips and equipment, while ABB adds more industrial muscle with a steadily rising trend. On the flip side, Advantest has been more of a roller coaster, recently losing some steam, and healthcare staples like Novartis and Roche have been mixed, acting more as stabilizers than sprinters. Overall, performance is driven by a concentrated cluster of non‑U.S. tech and industrial champions.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ― | 11.60% | $99.70M | ― | ― | ― | |
| ASML Holding NV | 6.80% | $58.47M | €619.66B | 138.67% | 76 Outperform | |
| Novartis AG | 3.76% | $32.34M | CHF219.47B | 25.25% | 80 Outperform | |
| Roche Holding AG | 3.58% | $30.74M | $328.05B | 25.86% | 73 Outperform | |
| Advantest | 3.54% | $30.47M | ¥20.52T | 131.31% | 75 Outperform | |
| Tokyo Electron | 2.93% | $25.18M | ¥33.07T | 168.48% | 73 Outperform | |
| Rolls-Royce Holdings | 2.85% | $24.45M | £113.56B | 54.92% | 71 Outperform | |
| SAFRAN SA | 2.54% | $21.80M | €131.91B | 26.44% | 67 Neutral | |
| ABB Ltd | 2.45% | $21.10M | CHF148.41B | 75.35% | 78 Outperform | |
| Allianz | 2.43% | $20.93M | €149.47B | 16.53% | 67 Neutral |
IDHQ Technical Analysis
Positive
―
Price Trends
40.06
Positive
38.59
Positive
36.43
Positive
Market Momentum
0.81
Negative
67.14
Neutral
89.05
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 41.44, equal to the 50-day MA of 40.06, and equal to the 200-day MA of 36.43, indicating a bullish trend. The MACD of 0.81 indicates Negative momentum. The RSI at 67.14 is Neutral, neither overbought nor oversold. The STOCH value of 89.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDHQ.
IDHQ Peer Comparison
Comparison Results
Performance Comparison
IDHQ
Invesco S&P International Developed High Quality ETF
43.92
12.36
39.16%
FYLD
Cambria Foreign Shareholder Yield ETF
―
―
―
TLTD
FlexShares Morningstar Developed Markets ex-US Factor Tilt
―
―
―
TXUE
Thornburg International Equity ETF
―
―
―
AVSD
Avantis Responsible International Equity ETF
―
―
―
MFDX
PIMCO RAFI Dynamic Multi-Factor International Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents